Local ablative therapy added to osimertinib for EGFR‑mutant metastatic NSCLC with few remaining tumor sites
Official title: ATOM2: A Randomized Phase II Trial on Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer After Osimertinib Treatment
Run by Chinese University of Hong Kong · NCT07379476 · Data updated 2026-11-12
This trial tests whether adding local ablative therapy to ongoing osimertinib helps people with EGFR exon 19 or exon 21 L858R mutated stage IV non‑small cell lung cancer who have three or fewer active tumor sites after initial treatment.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 64 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | osimertinib |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | February 11, 2026 |
| Main results expected | March 3, 2029 |
| Study ends | March 3, 2030 |
| Registry record updated | February 12, 2026 |
| Trial ID | NCT07379476 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with pathologically confirmed stage IV NSCLC harboring EGFR exon 19 deletion or exon 21 L858R who have received first‑line osimertinib for 12–24 weeks with no progression and have ≤3 active sites amenable to local ablative therapy are ideal candidates.
✕Probably not a fit
Patients with more than three active metastatic sites, documented progression on osimertinib, EGFR mutations other than exon 19 deletion or exon 21 L858R, symptomatic uncontrolled brain metastases, or lesions not suitable for local ablative therapy are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an open‑label, randomized phase II trial enrolling patients with stage IV NSCLC harboring EGFR exon 19 deletion or exon 21 L858R who have ≤3 active disease sites after 12–24 weeks of first‑line osimertinib. After confirmation of eligibility including PET‑CT and brain imaging, participants are randomized 1:1 to continue osimertinib alone or receive local ablative therapy (such as stereotactic radiotherapy or other physician‑selected LAT) to all oligoresidual sites in addition to osimertinib. The trial is multicenter and follows patients for disease control and survival outcomes, with CNS status accounted for in stratification. Treatment decisions about the type and timing of local ablative therapy are made by the treating physicians based on lesion location and patient factors.
Why it matters
Potential benefit: If successful, adding local ablative therapy could prolong disease control and delay progression for patients with limited residual metastatic sites while they remain on targeted osimertinib therapy.
How similar studies have gone: Prior randomized and phase II studies in oligometastatic NSCLC and smaller series combining local consolidative therapy with EGFR tyrosine kinase inhibitors have shown promising improvements in progression‑free survival, but definitive, large‑scale evidence in this specific setting is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older and able to understand and give written informed consent * Pathologically proven non-small cell lung cancer * Positive for EGFR exon 19 deletion or EGFR exon 21 L858R mutation (either by tissue or plasma testing) * Stage IV disease * Receive first line osimertinib monotherapy for stage IV disease * Undergo a PET-CT scan after 12-24 weeks of initiation of osimertinib treatment, with no evidence of disease progression, and less than or equal to 3 active disease sites (including primary tumour) amenable to local ablative therapy, as determined by investigator * At least one brain imaging (CT Brain or MRI Brain with contrast, preferably MRI Brain), either at time of diagnosis or while on osimertinib treatment but before randomization, to document CNS status for stratification. Patients with asymptomatic CNS metastases are eligible. For patients with brain metastases diagnosed at baseline, follow up brain imaging is recommended before randomization. * Patients with history of palliative radiotherapy are eligible * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate haematological values: haemoglobin ≥9.0g/dL, absolute neutreophil count ≥1.0 x 109/L, platelet count ≥100 x 109/L * Adequate hepatic function: bilirubin ≤1.5 x ULN, AST/ALT ≤2.5 x ULN * Adequate renal function: creatinine clearance ≥30ml/min, according to the formula of Cockcroft-Gault equation * Willing and able to comply with the requirements and restrictions in this protocol Exclusion Criteria: * Previous or concomitant malignancy within 5 years prior registration with the exception of adequately treated localized non-melanoma skin cancer or cervical cancer in situ. * Mixed SCLC and NSCLC histology * Positive pregnancy test * Contraindication to radiotherapy * Any serious underlying medical, psychiatric, psychological, familial condition that in the judgement of the investigator, that may interfere with planned staging, treatment and follow up, affect patient compliance, or place the patient at high risk from treatment related complications
Where it's running
-
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong Recruiting
Study contacts
- Study coordinator: Molly SC LI, MBBS, MRCP
- Email: molly@clo.cuhk.edu.hk
- Phone: 3505 1042
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Understanding what patients want from NSCLC treatment monitoring
Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.
-
Osimertinib with Cyclosporine A for EGFR-mutant NSCLC
This phase II study tests whether adding cyclosporine A to osimertinib helps people with EGFR-mutant metastatic NSCLC who still have detectable tumor DNA in blood.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC
This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.